A J Bridges

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

J. Smaill, W A Denny, J M Nelson, 2001, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

A. Bridges, D. W. Fry, A. McMichael, 1994, Science.